Investment House LLC lifted its position in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) by 4.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,760 shares of the company’s stock after purchasing an additional 360 shares during the quarter. Investment House LLC’s holdings in Biohaven Pharmaceutical were worth $665,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Biohaven Pharmaceutical by 7.9% in the second quarter. Vanguard Group Inc. now owns 1,504,787 shares of the company’s stock valued at $110,015,000 after purchasing an additional 110,271 shares during the period. FMR LLC raised its stake in Biohaven Pharmaceutical by 71.1% during the 2nd quarter. FMR LLC now owns 1,352,414 shares of the company’s stock valued at $98,875,000 after acquiring an additional 562,071 shares during the last quarter. Wells Fargo & Company MN raised its stake in Biohaven Pharmaceutical by 20.2% during the 3rd quarter. Wells Fargo & Company MN now owns 1,065,123 shares of the company’s stock valued at $69,244,000 after acquiring an additional 179,306 shares during the last quarter. Polar Capital LLP raised its stake in Biohaven Pharmaceutical by 33.8% during the 3rd quarter. Polar Capital LLP now owns 932,944 shares of the company’s stock valued at $60,651,000 after acquiring an additional 235,906 shares during the last quarter. Finally, Columbus Circle Investors raised its stake in shares of Biohaven Pharmaceutical by 19.6% during the 3rd quarter. Columbus Circle Investors now owns 600,871 shares of the company’s stock worth $39,063,000 after buying an additional 98,642 shares in the last quarter. Hedge funds and other institutional investors own 99.37% of the company’s stock.
In other Biohaven Pharmaceutical news, Director John W. Childs acquired 5,000 shares of Biohaven Pharmaceutical stock in a transaction dated Monday, November 23rd. The stock was acquired at an average cost of $89.55 per share, for a total transaction of $447,750.00. Following the completion of the transaction, the director now owns 2,516,938 shares in the company, valued at approximately $225,391,797.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gregory Bailey sold 4,554 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $78.98, for a total value of $359,674.92. Following the transaction, the director now owns 2,585,181 shares of the company’s stock, valued at $204,177,595.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,868 shares of company stock valued at $4,894,177. Insiders own 19.10% of the company’s stock.
Shares of BHVN stock opened at $90.40 on Thursday. The business has a 50 day moving average of $88.21 and a two-hundred day moving average of $75.65. Biohaven Pharmaceutical Holding Company Ltd. has a 52 week low of $26.56 and a 52 week high of $100.77. The company has a market cap of $5.42 billion, a P/E ratio of -7.37 and a beta of 1.09.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Monday, November 9th. The company reported ($3.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.74) by ($0.53). The business had revenue of $17.70 million during the quarter, compared to the consensus estimate of $19.35 million. During the same period in the prior year, the firm posted ($2.04) EPS. As a group, analysts anticipate that Biohaven Pharmaceutical Holding Company Ltd. will post -12.38 earnings per share for the current fiscal year.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.